{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:21:06Z","timestamp":1786735266653,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81772762"],"award-info":[{"award-number":["81772762"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Shanghai","award":["21ZR1450900"],"award-info":[{"award-number":["21ZR1450900"]}]},{"name":"Shanghai Science and Technology Planning Project","award":["21Y11907000"],"award-info":[{"award-number":["21Y11907000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04283-x","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:16:00Z","timestamp":1769490960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Yingjun","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4283_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110588","volume":"104","author":"MJ Quezada","year":"2023","unstructured":"Quezada MJ, Lopez-Bergami P (2023) The signaling pathways activated by ROR1 in cancer. Cell Signal 104:110588","journal-title":"Cell Signal"},{"key":"4283_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","volume":"5","author":"N Borcherding","year":"2014","unstructured":"Borcherding N, Kusner D, Liu GH, Zhang W (2014) Ror1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5:496\u2013502","journal-title":"Protein Cell"},{"key":"4283_CR3","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D et al (2017) Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res 23:3061\u20133071","journal-title":"Clin Cancer Res"},{"key":"4283_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2014.07.005","volume":"29","author":"M Hojjat-Farsangi","year":"2014","unstructured":"Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H (2014) The receptor tyrosine kinase ROR1\u2013an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol 29:21\u201331","journal-title":"Semin Cancer Biol"},{"key":"4283_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100001","volume":"1","author":"ML Wang","year":"2022","unstructured":"Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K, Kipps TJ et al (2022) Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid 1:EVIDoa2100001","journal-title":"NEJM Evid"},{"key":"4283_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-024-01782-0","volume":"26","author":"RA Shatsky","year":"2024","unstructured":"Shatsky RA, Batra-Sharma H, Helsten T, Schwab RB, Pittman EI, Pu M, Weihe E, Ghia EM, Rassenti LZ, Molinolo A et al (2024) A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced\/unresectable or metastatic Her2-negative breast cancer. Breast Cancer Res 26:32","journal-title":"Breast Cancer Res"},{"key":"4283_CR7","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1038\/srep05811","volume":"4","author":"H Zhang","year":"2014","unstructured":"Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y, Tang X, Xu N, Zhang D, Xiong L et al (2014) Ror1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 4:5811","journal-title":"Sci Rep"},{"key":"4283_CR8","doi-asserted-by":"publisher","first-page":"17266","DOI":"10.1073\/pnas.1419599111","volume":"111","author":"S Zhang","year":"2014","unstructured":"Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, Zhang Z, Wu CC, Chen L, Wu R et al (2014) Ovarian cancer stem cells express Ror1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA 111:17266\u201317271","journal-title":"Proc Natl Acad Sci USA"},{"key":"4283_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388\u2013398","journal-title":"Cancer Discov"},{"key":"4283_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C et al (2020) Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 13:30","journal-title":"J Hematol Oncol"},{"key":"4283_CR11","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41375-024-02392-7","volume":"38","author":"P Derigs","year":"2024","unstructured":"Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, R\u00f6themeier C, Neuber B, H\u00fcckelhoven-Krauss A, Br\u00fcggemann M et al (2024) Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study. Leukemia 38:2419\u20132428","journal-title":"Leukemia"},{"key":"4283_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","volume":"18","author":"J Yin","year":"2025","unstructured":"Yin J, Cui QY, Dai HP, Qu CJ, Li Z, Kang LQ, Cui W, Tian XP, Zhu XM, Yu L et al (2025) CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial. J Hematol Oncol 18:53","journal-title":"J Hematol Oncol"},{"key":"4283_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C (2022) Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 21:799\u2013820","journal-title":"Nat Rev Drug Discov"},{"key":"4283_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103599","author":"HX Lim","year":"2020","unstructured":"Lim HX, Kim TS, Poh CL (2020) Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21103599","journal-title":"Int J Mol Sci"},{"key":"4283_CR15","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W et al (2023) Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun 14:5110","journal-title":"Nat Commun"},{"key":"4283_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, Wang Y, Gao M, Hu X, Romero P et al (2024) IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol 42:1693\u20131704","journal-title":"Nat Biotechnol"},{"key":"4283_CR17","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","volume":"77","author":"W He","year":"2017","unstructured":"He W, Zhang H, Han F, Chen X, Lin R, Wang W, Qiu H, Zhuang Z, Liao Q, Zhang W et al (2017) CD155T\/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res 77:6375\u20136388","journal-title":"Cancer Res"},{"key":"4283_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.immuni.2022.12.010","volume":"56","author":"D Briukhovetska","year":"2023","unstructured":"Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Sch\u00fcbel M, Jobst J, Zhang T, D\u00f6rr J, M\u00e4rkl F et al (2023) T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity 56:143-161.e111","journal-title":"Immunity"},{"key":"4283_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/CIRCRESAHA.111.256834","volume":"110","author":"M Kinugasa","year":"2012","unstructured":"Kinugasa M, Amano H, Satomi-Kobayashi S, Nakayama K, Miyata M, Kubo Y, Nagamatsu Y, Kurogane Y, Kureha F, Yamana S et al (2012) Necl-5\/poliovirus receptor interacts with VEGFR2 and regulates VEGF-induced angiogenesis. Circ Res 110:716\u2013726","journal-title":"Circ Res"},{"key":"4283_CR20","first-page":"2960","volume":"17","author":"Y Xu","year":"2019","unstructured":"Xu Y, Cui G, Jiang Z, Li N, Zhang X (2019) Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett 17:2960\u20132968","journal-title":"Oncol Lett"},{"key":"4283_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/s41388-025-03322-2","volume":"44","author":"K Zhang","year":"2025","unstructured":"Zhang K, Mi Y, Zhang B, Xue X, Ding Y, Ma J, Yuan E, Zhao X, Zheng P (2025) Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers. Oncogene 44:1463\u20131474","journal-title":"Oncogene"},{"key":"4283_CR22","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2147\/OTT.S141476","volume":"10","author":"DW Huang","year":"2017","unstructured":"Huang DW, Huang M, Lin XS, Huang Q (2017) CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. Onco Targets Ther 10:3817\u20133825","journal-title":"Onco Targets Ther"},{"key":"4283_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.794","volume":"12","author":"AL Jin","year":"2022","unstructured":"Jin AL, Zhang CY, Zheng WJ, Xian JR, Yang WJ, Liu T, Chen W, Li T, Wang BL, Pan BS et al (2022) CD155\/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. Clin Transl Med 12:e794","journal-title":"Clin Transl Med"},{"key":"4283_CR24","doi-asserted-by":"publisher","first-page":"41.e11","DOI":"10.1016\/j.urolonc.2019.07.006","volume":"38","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zhu Y, Wang Q, Kong Y, Sheng H, Guo J, Xu J, Dai B (2020) Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis. Urol Oncol 38:41.e11-41.e18","journal-title":"Urol Oncol"},{"key":"4283_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108884","volume":"115","author":"H Yong","year":"2019","unstructured":"Yong H, Cheng R, Li X, Gao G, Jiang X, Cheng H, Zhou X, Zhao W (2019) CD155 expression and its prognostic value in postoperative patients with breast cancer. Biomed Pharmacother 115:108884","journal-title":"Biomed Pharmacother"},{"key":"4283_CR26","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","volume":"7","author":"L Wu","year":"2019","unstructured":"Wu L, Mao L, Liu JF, Chen L, Yu GT, Yang LL, Wu H, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ (2019) Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma. Cancer Immunol Res 7:1700\u20131713","journal-title":"Cancer Immunol Res"},{"key":"4283_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"4283_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457","journal-title":"Nat Methods"},{"key":"4283_CR29","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545\u201315550","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"4283_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36(5):411\u2013420","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4283_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, Chak S, Naikawadi RP, Wolters PJ, Abate AR, Butte AJ, Bhattacharya M (2019) Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 20(2):163\u2013172","journal-title":"Nat Immunol"},{"key":"4283_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","author":"EW Weber","year":"2021","unstructured":"Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, Good Z, Belk JA, Daniel B, Klysz D et al (2021) Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. https:\/\/doi.org\/10.1126\/science.aba1786","journal-title":"Science"},{"key":"4283_CR33","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R et al (2023) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29:2295\u20132306","journal-title":"Nat Med"},{"key":"4283_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C de Fern\u00e1nz Larrea","year":"2020","unstructured":"de Fern\u00e1nz Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, Purdon TJ, Ponomarev V, Wendel HG, Brentjens RJ, Smith EL (2020) Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov 1:146\u2013154","journal-title":"Blood Cancer Discov"},{"key":"4283_CR35","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","volume":"14","author":"RC Larson","year":"2023","unstructured":"Larson RC, Kann MC, Graham C, Mount CW, Castano AP, Lee WH, Bouffard AA, Takei HN, Almazan AJ, Scarf\u00f3 I et al (2023) Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat Commun 14:7509","journal-title":"Nat Commun"},{"key":"4283_CR36","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F et al (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109:17561\u201317566","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4283_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"4283_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/MOH.0000000000000239","volume":"23","author":"P Lertkiatmongkol","year":"2016","unstructured":"Lertkiatmongkol P, Liao D, Mei H, Hu Y, Newman PJ (2016) Endothelial functions of platelet\/endothelial cell adhesion molecule-1 (CD31). Curr Opin Hematol 23:253\u2013259","journal-title":"Curr Opin Hematol"},{"key":"4283_CR39","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284\u2013296","journal-title":"CA Cancer J Clin"},{"key":"4283_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, Nagao S, Vergote I, Colombo N, M\u00e4enp\u00e4\u00e4 J et al (2023) Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol 34:681\u2013692","journal-title":"Ann Oncol"},{"key":"4283_CR41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A et al (2023) Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol 41:609\u2013617","journal-title":"J Clin Oncol"},{"key":"4283_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","volume":"13","author":"S Narod","year":"2016","unstructured":"Narod S (2016) Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol 13:255\u2013261","journal-title":"Nat Rev Clin Oncol"},{"key":"4283_CR43","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544","journal-title":"N Engl J Med"},{"key":"4283_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439\u2013448","journal-title":"N Engl J Med"},{"key":"4283_CR45","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS (2024) CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332:1924\u20131935","journal-title":"JAMA"},{"key":"4283_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, Dermime S (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer 22:20","journal-title":"Mol Cancer"},{"key":"4283_CR47","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M (2025) CAR-T therapy in solid tumors. Cancer Cell 43:665\u2013679","journal-title":"Cancer Cell"},{"key":"4283_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20:49\u201362","journal-title":"Nat Rev Clin Oncol"},{"key":"4283_CR49","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA (2015) CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125:4017\u20134023","journal-title":"Blood"},{"key":"4283_CR50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","volume":"132","author":"DJ Green","year":"2018","unstructured":"Green DJ, Pont M, Sather BD, Cowan AJ, Turtle CJ, Till BG, Nagengast AM, Libby EN III, Becker PS, Coffey DG et al (2018) Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Blood 132:1011\u20131011","journal-title":"Blood"},{"key":"4283_CR51","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:2561\u20132569","journal-title":"N Engl J Med"},{"key":"4283_CR52","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","volume":"96","author":"S Liu","year":"2021","unstructured":"Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, Pan J, Yu X, Chen B, Wu T et al (2021) Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol 96:671\u2013679","journal-title":"Am J Hematol"},{"key":"4283_CR53","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK et al (2016) Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest 126:3036\u20133052","journal-title":"J Clin Invest"},{"issue":"1","key":"4283_CR54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ygyno.2020.04.689","volume":"158","author":"J Smazynski","year":"2020","unstructured":"Smazynski J, Hamilton PT, Thornton S et al (2020) The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecol Oncol 158(1):167\u2013177","journal-title":"Gynecol Oncol"},{"issue":"4","key":"4283_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152982","volume":"11","author":"A Iguchi-Manaka","year":"2016","unstructured":"Iguchi-Manaka A, Okumura G, Kojima H et al (2016) Increased soluble CD155 in the serum of cancer patients. PLoS ONE 11(4):e0152982","journal-title":"PLoS ONE"},{"issue":"15","key":"4283_CR56","doi-asserted-by":"publisher","first-page":"e189920","DOI":"10.1172\/JCI189920","volume":"135","author":"T Xiong","year":"2025","unstructured":"Xiong T, Wang G, Yu P et al (2025) CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors. J Clin Invest 135(15):e189920","journal-title":"J Clin Invest"},{"key":"4283_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"4283_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004219","author":"X Zhu","year":"2022","unstructured":"Zhu X, Liang R, Lan T, Ding D, Huang S, Shao J, Zheng Z, Chen T, Huang Y, Liu J et al (2022) Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004219","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04283-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:02:40Z","timestamp":1769493760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04283-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4283"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04283-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests. All the authors approved the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"44"}}